CHICAGO (AP) — The Rev. Jesse Jackson disclosed publicly Friday that he has been seeking outpatient care for two years for Parkinson's disease and plans to "dedicate" himself to physical therapy.In a Friday letter to supporters, the 76-year-old civil rights leader said family and friends noticed a change in him about three years ago. He said he could no longer ignore symptoms of the chronic neurological disorder that causes movement difficulties."Recognition of the effects of this disease on me has been painful, and I have been slow to grasp the gravity of it," he wrote.
NYS Entity Status
NYS Filing Date
JUNE 23, 2014
NYS DOS ID#
NYS Entity Type
DOMESTIC PROFESSIONAL CORPORATION
2014 - ME FREEDOM PHYSICAL THERAPY P.C.
Around the Web
- Rev Jesse Jackson discloses Parkinson's disease diagnosis
By SOPHIA TAREEN, Associated Press - Friday Nov 17, 2017
- Bots are becoming highly skilled assistants in physical therapy
By Michal Prywata, Bionik Laboratories - Sunday Oct 15, 2017
GUEST: Within the last decade, we’ve seen incredible progress in the fields of robotics and artificial intelligence. Innovators have been seeking out ways to meld man and machine and, in some areas, remove man altogether. In robotics, we’re seeing delivery drones, security robots, and more. In AI, chatbots, self-driving cars, and voice recognition have all made […]
- Let's Analyze the Ridiculous Physics of the Bugatti Chiron
By Rhett Allain - Friday Oct 6, 2017
There's basically zero chance of me not doing a speed analysis of this thing.
- The Rebuilding Years, Post-Sandy
By THE NEW YORK TIMES and JONAH MARKOWITZ - Sunday Oct 29, 2017
Those affected by Hurricane Sandy five years ago shared how the storm changed their lives physically, emotionally and financially, and how things have changed for the better since.
- Stealthy NY Startup Rocket Pharma Merges With Inotek, Heads to Nasdaq
By Ben Fidler - Tuesday Sep 12, 2017
Rocket Pharmaceuticals, a stealthy gene therapy startup in New York City, has made its first splash. Through a merger with struggling Inotek Pharmaceuticals (NASDAQ: ITEK), Rocket, a company developing treatments for a variety of rare blood diseases, has taken itself public. Rocket shareholders are expected to own 81 percent of the combined company, with Inotek […]